Why the study?
Does the pan-immune-inflammation value (PIV) predict long-term mortality better than other inflammation markers in patients with ST-segment elevation myocardial infarction?
Does the pan-immune-inflammation value (PIV) predict long-term mortality better than other inflammation markers in patients with ST-segment elevation myocardial infarction?
Answers are grounded in this paper and cite their sources.
The pan-immune-inflammation value (PIV) may serve as a superior prognostic biomarker for long-term mortality in patients following STEMI.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Çaylı et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: